Skip to main content

Summary

for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion:

Description

Summary

This study is designed to assess the usefulness of 18F-AV-1451 in Positron Emission Tomography imaging for subjects diagnosed with Frontotemporal Dementia.

Official Title

18F-AV-1451 PET Imaging in Subjects With Frontotemporal Dementia

Keywords

Frontotemporal Dementia Dementia Aphasia, Primary Progressive Pick Disease of the Brain

Eligibility

You can join if…

Open to people ages 18 years and up

  • Have provided informed consent or have a legally authorized (LAR) provide consent for study procedures
  • Have had volumetric brain MRI obtained in site's companion protocol within one year of enrollment
  • Can tolerate PET scan procedures

You CAN'T join if...

  • Have clinically significant cardiac, hepatic, renal, pulmonary, metabolic, or endocrine disturbances that pose potential safety risk
  • Have history of risk factors for Torsades de Pointes (TdP) or taking medication known to cause QT prolongation
  • Have history of drug or alcohol dependence within the last year
  • Are females of childbearing potential who are not surgically sterile, not refraining from sexual activity, or not using reliable contraception
  • Have history of relevant severe drug allergy or hypersensitivity
  • Have received an investigational medication under FDA IND protocol within 30 days of planned imaging session
  • Have received a radiopharmaceutical for imaging/therapy within 24 hours of imaging session
  • Possess PET scan evidence of amyloid deposition
  • Determined by the investigator to be unsuitable for this type of study

Locations

  • Memory and Aging Center, UCSF accepting new patients
    San Francisco, California, 94158, United States
  • Movement Disorder Center, UCSD accepting new patients
    La Jolla, California, 92037, United States
  • UT Southwestern Medical Center accepting new patients
    Dallas, Texas, 75390, United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Avid Radiopharmaceuticals
ID
NCT03040713
Phase
Phase 1
Study Type
Interventional
Last Updated
July 25, 2017
I’m interested in this study!